Form 4: Omnicell Director Mary Garrett Receives Equity Grant for Board Service

Omnicell, Inc. Director Mary Garrett was granted 7,084 restricted shares of common stock on June 1, 2025, as compensation for her board service, increasing her total beneficial ownership to 17,175 shares.

Summary

• Mary Garrett, a Director of Omnicell, Inc. (OMCL), acquired 7,084 shares of Common Stock on June 1, 2025.
• The acquisition was a grant of restricted shares under the Issuer's equity incentive plan and Board of Directors Compensation Plan.
• These shares were granted in consideration of services as a Board Member.
• The granted shares are scheduled to vest in full on the one-year anniversary of the grant date, which is June 1, 2026.
• Following this transaction, Mary Garrett's total beneficial ownership of Omnicell Common Stock is 17,175 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive as the filing indicates a routine equity grant to a director, which is a common practice to align management/board interests with shareholders and retain talent. It does not contain any negative financial or operational news.

Positives

• Alignment of interests: The grant of restricted shares to a director aligns her interests with those of shareholders, as her compensation is tied to the company's long-term performance.
• Retention of talent: Equity grants are a common mechanism to retain experienced and valuable board members, ensuring continuity in governance.

Negatives

• No direct negatives are apparent from this specific Form 4 filing, which primarily reports a routine equity compensation grant.

Risks

• No specific risks are detailed in this Form 4 filing, as it is a disclosure of insider stock transactions rather than a comprehensive risk assessment document.

Future Outlook

The granted restricted shares are scheduled to vest in full on the one-year anniversary of the grant date, which is June 1, 2026, indicating a future milestone for the reporting person's equity ownership.

Management Comments

• This Form 4 filing does not contain direct quotes or paraphrased statements from company management, as it is a regulatory disclosure of an insider transaction.

Industry Context

The grant of restricted shares to a board member is a standard practice across many industries, including healthcare technology, to compensate directors for their service and align their long-term interests with those of the company's shareholders. This practice is common for publicly traded companies like Omnicell.

Comparison to Industry Standards

• This Form 4 filing does not provide sufficient detail to compare the specific compensation package or equity grant size to industry benchmarks or comparable companies. Such comparisons would require a review of Omnicell's proxy statements and compensation disclosures relative to its peers in the healthcare technology sector.

Management Changes

Corporate Governance

Legal Proceedings

• No legal proceedings or regulatory matters are mentioned in this Form 4 filing.

Related Party Transactions

• The grant of restricted shares to Mary Garrett, a director, constitutes a related party transaction as it involves compensation provided by the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially encouraging decisions that enhance long-term shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing, as it pertains to director compensation.

Next Steps

• The restricted shares granted to Mary Garrett are scheduled to vest in full on June 1, 2026.

Key Dates

Keywords

Omnicell, OMCL, Form 4, Insider Trading, Equity Grant, Restricted Stock, Director Compensation, Corporate Governance, Stock Ownership